english.prescrire.org > Prescrire International > N°273 - September 2025

n°273

September 2025

Issue Contents
Editorial

Free  Pricing of new drugs: deadlock

p.199

Marketing Authorisations


Live attenuated cholera O1 vaccine (Vaxchora°)

p.201-205

Editors' opinion. Nothing new

p.203

Relugolix + estradiol + norethisterone acetate (Ryeqo°) in endometriosis

p.205-206

Quizartinib (Vanflyta°) in acute myeloid leukaemia with an FLT3-ITD mutation

p.207-208

Pembrolizumab (Keytruda°) before and after surgery in certain triple-negative breast cancers

p.208-209

Talquetamab (Talvey°) in multiple myeloma after at least 3 lines of treatment

p.210

Editors' opinion. Two birds with one stone

p.210

Dupilumab (Dupixent°) in certain forms of chronic obstructive pulmonary disease (COPD)

p.211-212

Atezolizumab for subcutaneous injection (Tecentriq°)

p.212-213

Trifluridine + tipiracil (Lonsurf°) + bevacizumab in metastatic colorectal cancer after 2 lines of treatment

p.213-214

Adverse Effects


Long-term PPI treatment: increased incidence of gastric cancer and gastric cancer recurrence

p.215-216

Common stem: -copan

p.216

Hyponatraemia on thiazide diuretics: from the very first days of exposure

p.217-218

PD-1 or PD-L1 immune checkpoint inhibitors: cholangitis

p.219

Fluoroquinolones: intracranial hypertension

p.220

ACE inhibitors: sometimes severe forms of psoriasis

p.221

Outlook


Health literacy: major difficulties in France

p.222

Free  Antineoplastic drugs that do not represent a therapeutic advance: still highly profitable

p.222-223

Free  Anti-competitive practices: a very "inventive" pharmaceutical industry

p.223

Masthead


Free  Masthead

p.198

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe